Answers are grounded in this paper and cite their sources.
This review compares upfront surgery with neoadjuvant treatment for better outcomes in borderline resectable pancreatic cancer, suggesting a shift in treatment strategy.
Neoadjuvant therapy, utilizing potent multi-agent regimens, significantly improves R0 resection rates and overall survival in BRPC and is increasingly recognized as the preferred clinical strategy. Currently, this survival benefit is not clearly established for patients with upfront resectable disease.
No takes yet. Share an insight, caveat, or question.
Nan‐ak Wiboonkhwan (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: